User profiles for Edwin R. Parra
 | Edwin Roger Parra CuentasDr. Faculdade de Medicina da Universidade de São Paulo Verified email at usp.br Cited by 12330 |
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
…, J Rodriguez-Canales, PA Villalobos, ER Parra… - Cancer discovery, 2018 - AACR
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously
reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of …
reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of …
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
…, ER Parra, I Wistuba, V Calvo, R Laza-Briviesca… - The Lancet …, 2020 - thelancet.com
Background Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally
advanced stage disease. We aimed to assess the antitumour activity and safety of neoadjuvant …
advanced stage disease. We aimed to assess the antitumour activity and safety of neoadjuvant …
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small
cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment …
cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment …
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic …
The molecular underpinnings that drive the heterogeneity of KRAS-mutant lung
adenocarcinoma are poorly characterized. We performed an integrative analysis of genomic, …
adenocarcinoma are poorly characterized. We performed an integrative analysis of genomic, …
[HTML][HTML] Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT)
induce greater pathologic response rates than CT alone in patients with operable non-small …
induce greater pathologic response rates than CT alone in patients with operable non-small …
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
…, H Abu-Sbeih, CA Sanchez, CC Chang, ER Parra… - Nature medicine, 2018 - nature.com
We report the first case series of immune checkpoint inhibitors (ICI)-associated colitis successfully
treated with fecal microbiota transplantation, with reconstitution of the gut microbiome …
treated with fecal microbiota transplantation, with reconstitution of the gut microbiome …
A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition
…, DL Gibbons, WN William, F Skoulidis, ER Parra… - Clinical Cancer …, 2016 - AACR
Purpose: We previously demonstrated the association between epithelial-to-mesenchymal
transition (EMT) and drug response in lung cancer using an EMT signature derived in cancer …
transition (EMT) and drug response in lung cancer using an EMT signature derived in cancer …
[HTML][HTML] The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and …
…, TJ Hollmann, J Juco, ER Parra… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Objectives The interaction between the immune system and tumor cells is an important feature
for the prognosis and treatment of cancer. Multiplex immunohistochemistry (mIHC) and …
for the prognosis and treatment of cancer. Multiplex immunohistochemistry (mIHC) and …
[HTML][HTML] Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor …
Immune-profiling is becoming an important tool to identify predictive markers for the response
to immunotherapy. Our goal was to validate multiplex immunofluorescence (mIF) panels to …
to immunotherapy. Our goal was to validate multiplex immunofluorescence (mIF) panels to …
Association of interferon‐and transforming growth factor β–regulated genes and macrophage activation with systemic sclerosis–related progressive lung fibrosis
…, R Kairalla, ER Parra, A Spira, R Simms… - Arthritis & …, 2014 - Wiley Online Library
Objective Systemic sclerosis (SSc)–related interstitial lung disease (ILD) is one of the leading
causes of mortality. We undertook this study to analyze the gene expression of lung tissue …
causes of mortality. We undertook this study to analyze the gene expression of lung tissue …
